Abstract: A computer program product includes machine readable instructions stored on machine readable media, the instructions for correlating nuclear magnetic resonance (NMR) well logging data with other well logging data, the product including instructions for: receiving the NMR well logging data; receiving the other well logging data; determining a tendency of the NMR logging data to correlate with the other logging data and providing output including correlation information. A system is also provided.

Abstract: A manual wheelchair loader design to lift and place an article, such as a collapsible wheelchair, into the cargo area of a vehicle. The loader includes a base adapted to rest on a substantially flat surface within the vehicle. At least one support arm is connected to the base to hold a carriage. The carriage is adapted to rotate between a first position and a second position. The carriage further has a lower support surface adapted to support the article being loaded when the frame is in a first position. The carriage also has a lateral support surface adapted to support the article being loaded when the carriage is in a second position. A ramp is hingedly connected to lower support surface for wheeling the article thereto.

Abstract: Nucleic acid molecules which encode decapeptides which are defined by an HLA-A2 binding motif are disclosed. Also disclosed are expression vectors which include these nucleic acid molecules.

Abstract: Biological and chemical systems are represented as a symbolic model. Minimal sets of elements of the system are identified from the model, for example, by automatic inference. The model can be constructed from Boolean propositions that are mapped to a binary decision diagram. The model can also be probed using a branch and bound algorithm.

Abstract: The invention relates to immunoconjugates of formula: A-B—(C)n where B may be present or absent, A is a specific binding protein such as an antibody or an antibody binding fragment, or a ligand binding to a receptor present on target cells B comprises at least one molecule to which “A” and “C” bind, such as an avidin/streptavidin complex, “C” is an MHC molecule, and “n” is a whole number ranging from 1 to 10. The conjugates provide the exquisite binding specificity of antibodies, combined with an ability to stimulate cytotoxic T cells to identify and to destroy cells on which the conjugate is bound and oligomerized. The conjugates are useful both therapeutically and diagnostically.

Abstract: Nonapeptides and decapeptides which bind to HLA molecules and provoke proliferation of cytolytic T cells are disclosed. The decapeptides terminate in Valine, and are restricted in their first three amino acid positions. Other useful nonapeptides are also disclosed.

Abstract: The invention relates to immunoconjugates of formula:

Abstract: The invention relates to immunoconjugates of formula: A—B—(C)n where B may be present or absent, A is a specific binding protein such as an antibody or an antibody binding fragment, or a ligand binding to a receptor present on target cells, B comprises at least one molecule to which “A” and “C” bind, such as an avidin/strepavidin complex, “C” is an MHC molecule, and “n” is a whole number ranging from 1 to 10. The conjugates provide the exquisite binding specificity of antibodies, combined with an ability to stimulate cytotoxic T cells to identify and to destroy cells on which the conjugate is bound and oligomerized. The conjugates are useful both therapeutically and diagnostically.

Abstract: The invention relates to variant peptides which bind to HLA molecules, leading to lysis of cells via cytolytic T cell lines. The variants are based upon NY-ESO-1 peptides. The peptides can be incorporated into immune tetramers, which are useful as T cell sorters.

Abstract: Nonapeptides and decapeptides which bind to HLA molecules and provoke proliferation of cytolytic T cells are disclosed. The decapeptides terminate in Valine, and are restricted in their first three amino acid positions. Other useful nonapeptides are also disclosed.

Abstract: The invention relates to variant peptides which bind to HLA molecules, leading to lysis of cells via cytolytic T cell lines. The variants are based upon NY-ESO-1 peptides. The peptides can be incorporated into immune tetramers, which are useful as T cell sorters.

Abstract: Nonapeptides and decapeptides which bind to HLA molecules and provoke proliferation of cytolytic T cells are disclosed. The decapeptides terminate in Valine, and are restricted in their first three amino acid positions. Other useful nonapeptides are also disclosed.

Abstract: Nonapeptides and decapeptides which bind to HLA molecules and provoke proliferation of cytolytic T cells are disclosed. The decapeptides terminate in Valine, and are restricted in their first three amino acid positions. Other useful nonapeptides are also disclosed.

Abstract: Cytolytic T cells specific to complexes J HLA-A2 molecules and peptides are described as are methods for provoking the cytolytic T cells. The peptides of SEQ ID NOS: 13, 14 and 15 are preferred peptides.

Abstract: Nonapeptides and decapeptides which bind to HLA molecules and provoke proliferation of cytolytic T cells are disclosed. The decapeptides terminate in Valine, and are restricted in their first three amino acid positions. Other useful nonapeptides are also disclosed.

Abstract: The invention involves nonapeptides bound by HLA molecules such as HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.

Abstract: Nonapeptides and decapeptides which bind to HLA molecules and provoke proliferation of cytolytic T cells are disclosed. The decapeptides terminate in Valine, and are restricted in their first three amino acid positions. Other useful nonapeptides are also disclosed.

Abstract: The invention relates to methods for making synthetic, photoreactive peptides and their use. A photoreactively labelled amino acid is incorporated into the peptide. The resulting peptide, when compared to the non-labelled form, is not impaired with respect to its ability to bind an MHC molecule.

Abstract: A stable human serum based control for the assay of Total LD and CK and their isoenzymes. This control may be lyophilized and reconstituted and still provide the same enzyme activity prior to lyophilization, for seven (7) days after reconstitution, if stored in the dark at or about 2.degree.0 to 8.degree. C. No thiol compounds other than the amount normally used to purify CK isoenzymes are found in this highly stable control.